Kodosil Bio focuses on developing treatments with antibodies for bowel disease and cancers and was formed as the result of a strategic licensing agreement between BioMotiv and BioAtla.
BioMotiv as a company is interested in licensing technologies and sourcing products from preclinical through early clinical stages of development, while BioAlta provides its proprietary platform for identifying and developing promising therapeutics antibodies.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
Pipeline
IL-22 antibody is directed at a novel validated target in the TH22 cell/IL-22 pathway, and has high expression levels in colorectal cancer (CRC) patients.
In Feb 2014, BioAlta grants Kodosil Bio (promoted by BioMotiv) an exclusive worldwide development rights to IL-22 antibody for inflammatory bowel diseases (IBD) and oncologic indications.
Recover your password.
A password will be e-mailed to you.